

RESEARCH LETTER

Association of Hypertension With Early-Onset Cryptogenic Ischemic Stroke by the Presence of Patent Foramen Ovale: A Case–Control Study

Jukka Putaala , MD; Bettina von Sarnowski , MD; Ulf Schminke , MD; Raila Busch, MD; Nicolas Martinez-Majander , MD; Pauli Ylikotila, MD; Riikka Lautamäki, MD; Marialuisa Zedde , MD; Teresa Grimaldi, MD; Tomi Sarkanen , MD; Marko Virtanen , MD; Kristina Ryliskiemi , MD; Diana Zakarkaite , MD; Lauri Tulkki , MD; Jani Pirinen, MD; Radim Licenik, MD; Phillip Ferdinand, MD; Cheryl Oxley, BSc; Janika Kõrv , MD; Piibe Muda, MD; Alessandro Pezzini , MD; Carlo Mario Lombardi , MD; Georgios Tsivgoulis , MD; Satu Suihko, MD; Heli Tolppanen , MD; Ana Catarina Fonseca , MD; Patricia Martínez-Sánchez , MD; Laura Amaya Pascasio , MD; Nilufer Yesilot , MD; Ali Elitok, MD; Ulrike Waje-Andreassen , MD; Sahrai Saeed , MD; Petra Redfors, MD; Odd Bech-Hanssen, MD; Juha Huhtakangas, MD; Marja Hedman , MD; Pekka Jäkälä , MD; Juha Sinisalo , MD; Eva Gerdts , MD; the SECRETO Study Group*

Cryptogenic ischemic stroke (CIS) in the young represents a crucial area of research due to its substantial clinical burden and increasing incidence.¹ Hypertension stands as the most prevalent well-documented stroke risk factor. However, there are limited and conflicting data on the prevalence of hypertension and associations of hypertension with ischemic stroke in young patients with cryptogenic pathogenesis.^{2,3} Although patent foramen ovale (PFO) is an important phenotypic feature of CIS, the association of hypertension in patients with CIS with or without PFO has not been specifically addressed in previous studies. These studies may have mixed PFO cases between cardioembolic and undetermined pathogenetic subgroups. Young patients with CIS and PFO are less likely to have hypertension and other traditional

risk factors, and most recent evidence suggests that specific high-risk features of PFO (atrial septal aneurysm or a large-sized shunt) substantially increase the causality of PFO.⁴ We determined the sex- and age-specific prevalence and association of hypertension in early-onset CIS stratified by the high-risk PFO (HR-PFO) phenotype.

We included 523 consecutive young patients aged 18 to 49 years with CIS (median age, 40.8 [interquartile range, 34.1–45.8]; 47.2% women) from the Searching for Explanations for Cryptogenic Stroke in the Young study and 1:1 age- and sex-matched stroke-free controls across 19 European centers. Data on HR-PFO were unavailable for 23 of the initial 546 patients because shunt size was not reported due to various reasons, such as poor visibility and technical difficulties. Ethical

Key Words: blood pressure ■ foramen ovale, patent ■ hypertension ■ ischemic stroke ■ risk factors

Correspondence to: Jukka Putaala, MD, Department of Neurology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, Helsinki 00290, Finland. Email: jukka.putaala@hus.fi

*A complete list of the SECRETO Study Group members can be found in the Supplemental Material.

This manuscript was sent to Michelle H. Leppert, MD, MBA, Associate Editor, for review by expert referees, editorial decision, and final disposition.

Registration: URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT01934725.

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.036254>

For Sources of Funding and Disclosures, see page 4.

© 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

approval was obtained from local committees and written informed consent from all participants. The data that support the findings of this study are available from the corresponding author upon reasonable request. Patients underwent standardized pathogenetic examinations as detailed before.⁵ Hypertension was defined as a prior diagnosis, prior antihypertensive medication use, or a mean of 2 office blood pressure measures $\geq 140/90$ at study visit (median 6 days from stroke onset in patients). Comorbidities included cardiovascular disease, diabetes, hypercholesterolemia, current smoking, abdominal obesity, physical inactivity, unhealthy diet, heavy alcohol use, psychosocial stress, and depression. HR-PFO in patients with CIS was assessed by local investigators and defined as PFO with atrial septal

aneurysm or PFO with a large-sized right-to-left shunt (≥ 25 microbubbles crossing the atrial septum), identified through transthoracic or transesophageal echocardiogram, often supported by transcranial Doppler bubble test. In patients with CIS, we assessed the association of hypertension with the absence of HR-PFO with logistic regression, adjusting for demographics and all other comorbidities. Using all stroke-free controls, we constructed logistic regression models to assess the association of hypertension with (1) CIS without HR-PFO and (2) CIS with HR-PFO, stratifying by sex and age group (18–39 and 40–49 years). We also tested for sex and age interactions. Adjustments included demographics alone, demographics with standardized modifiable stroke risk factors (cardiovascular disease, diabetes,




Figure. Frequencies of hypertension in the study population and multivariable analysis of the association between hypertension and early-onset cryptogenic ischemic stroke.

A, Frequencies and 95% CIs of hypertension in patients with cryptogenic ischemic stroke without high-risk patent foramen ovale (HR-PFO), patients with HR-PFO, and stroke-free controls, shown for the overall cohort and by demographic subgroups. **B,** Odds ratios (ORs) with 95% CIs for the association of hypertension with cryptogenic ischemic stroke in the overall cohort, women, men, those aged 18 to 39 years, and those aged 40 to 49 years, stratified by the presence of HR-PFO in patients. Model 1 is adjusted for demographics (age, sex, and level of education). Model 2 is adjusted for demographics and standardized stroke risk factors (SSRFs) including cardiovascular disease, diabetes, hypercholesterolemia, and current smoking, when frequency allowed. Model 3 was further adjusted for abdominal obesity, physical inactivity, unhealthy diet, heavy alcohol use, psychosocial stress, and depression.

hypercholesterolemia, and current smoking), and demographics with all comorbidities. Statistical analyses used IBM SPSS Statistics 29.0 and R (R Core Team 2023).

Compared with patients with CIS without hypertension ($n=359$ [65.2%]), patients with hypertension ($n=182$ [34.8%]) were older (43.8 versus 39.2 years), and more frequently had cardiovascular disease (4.4% versus 1.2%), diabetes (4.9% versus 1.8%), hypercholesterolemia (5.5% versus 0.6%), abdominal obesity (79.1 versus 48.7%), and low physical activity (34.6% versus 26.0%), and more often they reported psychosocial stress (57.1% versus 45.3%). Patients with hypertension less frequently had HR-PFO (25.8% versus 43.7%). Among patients with CIS, hypertension was associated with absence of HR-PFO (odds ratio, 2.11 [95% CI, 1.36–3.27]).

Compared with all stroke-free controls ($n=542$), patients without HR-PFO ($n=327$ [62.5%]) more frequently had hypertension in the overall cohort, across sexes, and in the older age group overall and in men. Among women in both age groups, there was a trend of higher hypertension prevalence in patients without HR-PFO, although the confidence intervals overlapped. No significant differences emerged between patients with HR-PFO ($n=196$) and controls (Figure [A]).

In multivariable case–control analyses, hypertension showed a significant association for CIS without HR-PFO across all models in the overall cohort, whereas no association emerged for CIS with HR-PFO. The strength of the association between hypertension and CIS without HR-PFO tended to diminish when behavioral risk factors were included in the models. In sex-specific analyses, we initially observed an association between hypertension and CIS with HR-PFO with less stringent adjustment, which did not persist after full adjustment, with no interaction by sex ($P=0.545$). Age-specific models adjusted for all relevant confounders showed association for CIS without HR-PFO specifically among individuals aged 40 to 49 years (Figure [B]), with no formal interaction observed by age ($P=0.469$).

The main findings of this study were that hypertension was highly prevalent in patients with early-onset CIS without PFO across sexes and with age, and that the independent association between hypertension and CIS considered only the patients without HR-PFO but not those with HR-PFO, a phenotype most likely connected to CIS through paradoxical embolism. The overall prevalence of hypertension in our patients with CIS without HR-PFO aligns with the range reported in larger series of unselected young patients with ischemic stroke.^{2,3} In contrast, those with HR-PFO exhibited a prevalence below the range reported, but aligning (that shown) in pooled data set results of all-aged patients with PFO from randomized trials.⁴ Hypertension was independently associated with CIS without HR-PFO, without interaction for age and sex, although in

demographic subgroups our power to show significant differences was limited. However, our results expand previous case–control studies involving unselected young patients with ischemic stroke, which indicated a stronger association between hypertension and age.^{2,3} Hypertension probably contributes to early-onset CIS (assuming most events are not related to atherosclerotic disease) in patients without HR-PFO through various cardiac and arterial mechanisms, including left ventricular hypertrophy, left atrial stiffness, vulnerability to paroxysmal atrial fibrillation, endothelial dysfunction, reduced fibrinolytic capacity, and cerebral hemodynamic alterations. The attenuation of the association's strength following further adjustments in our models may indicate that behavioral risk factors beyond smoking significantly contribute to early-onset CIS, potentially through processes involved in the development of hypertension.

The most notable strengths of our study are the relatively large sample of prospectively and consecutively identified young patients with CIS, detailed characterization of participants, and extensive adjustment for relevant confounders. Limitations include restricted sample size for subgroup analyses and those inherent to case–control studies, such as possible selection bias with controls. However, the prevalence of comorbidities, including hypertension among control subjects, is in line with contemporary estimates.

ARTICLE INFORMATION

Received May 24, 2024; accepted July 22, 2024.

Affiliations

Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland (J.P., N.M., L.T.); Department of Neurology (B.v.S., U.S.), and Department of Internal Medicine B (Cardiology) (R.B.), University Medicine Greifswald, Greifswald, Germany, Department of Neurology, Turku University Hospital and University of Turku, Finland (P.Y.); Heart Center, Turku University Hospital, Turku, Finland (R.L.); Neurology Unit, Stroke Unit (M.Z.), and Cardiology Unit (T.G.), Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy; Department of Neurology, Tampere University Hospital, Wellbeing Services County of Pirkanmaa and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (T.S.); Heart Hospital, Tampere University Hospital, Tampere, Finland (M.V.); Faculty of Medicine, Center of Neurology, Vilnius University, Vilnius, Lithuania (K.R., D.Z.); Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland (J.P., S.S., H.T., J.S.); Stroke, Peterborough City Hospital, Peterborough, United Kingdom (R.L.); Neurosciences (P.F.), and Cardiac Physiology Services (C.O.), University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom; Department of Neurology and Neurosurgery (J.K.), and Department of Cardiology (P.M.), University of Tartu, Estonia, VAI Stroke Care Program, Department of Emergency, Parma University Hospital, Parma, Italy (A.P.); Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy (C.M.L.); Second Department of Neurology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece (G.T.); Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Portugal (A.C.F.); Department of Neurology, Torrecardenas University Hospital, University of Almería, Spain (P.M.S., L.A.P.); Department of Neurology (N.Y.) and Department of Cardiology (A.E.), Istanbul University Faculty of Medicine, Istanbul, Turkey, Department of Neurology (U.W.) and Department of Heart Disease (S.S.), Haukeland University Hospital, Bergen, Norway, Department of Neurology, Sahlgrenska University Hospital and Department of Clinical Neuroscience, Institute of Neuroscience and Physiology (P.R.) and Department

of Clinical Physiology, Institute of Medicine (O.B.), Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Neurology, Oulu University Hospital and University of Oulu, Finland (J.H.); Heart Center, Kuopio University Hospital, Kuopio, Finland (M.H.); Neurocenter Neurology, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland (P.J.); University of Eastern Finland, Kuopio, Finland (P.J.); and Center for Research on Cardiac Disease in Women, Department of Clinical Science, University of Bergen, Norway (E.G.).

Sources of Funding

This work was supported by the Helsinki and Uusimaa Hospital District Fund (TYH2014407, TYH2018318), Academy of Finland (286246, 318075, 322656), Finnish Medical Foundation; and Sigrid Juselius Foundation.

Disclosures

Dr Putala is a board member of the Finnish Hypertension Association. Dr Fonseca is a speaker for Novo Nordisk. The remaining authors have no disclosures to report.

Supplemental Material

Data S1

REFERENCES

1. Li L, Scott CA, Rothwell PM. Association of Younger vs older ages with changes in incidence of stroke and other vascular events, 2002–2018. *JAMA*. 2022;328:563–574. doi: [10.1001/jama.2022.12759](https://doi.org/10.1001/jama.2022.12759)
2. Aigner A, Grittner U, Rolfs A, Norrving B, Siegerink B, Busch MA. Contribution of established stroke risk factors to the burden of stroke in young adults. *Stroke*. 2017;48:1744–1751. doi: [10.1161/STROKEAHA.117.016599](https://doi.org/10.1161/STROKEAHA.117.016599)
3. Kivioja R, Pietilä A, Martinez-Majander N, Gordin D, Havulinna AS, Salomaa V, Aarnio K, Curtze S, Leiviskä J, Rodríguez-Pardo J, et al. Risk factors for early-onset ischemic stroke: a case-control study. *J Am Heart Assoc*. 2018;7:e009774. doi: [10.1161/JAHA.118.009774](https://doi.org/10.1161/JAHA.118.009774)
4. Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, Derumeaux G, Furlan AJ, Herrmann HC, Jüni P, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. *JAMA*. 2021;326:2277–2286. doi: [10.1001/jama.2021.20956](https://doi.org/10.1001/jama.2021.20956)
5. Putala J, Martinez-Majander N, Saeed S, Yesilot N, Jäkälä P, Nerg O, Tsvigoulis G, Numminen H, Gordin D, von Sarnowski B, et al. Searching for explanations for cryptogenic stroke in the young: revealing the triggers, causes, and outcome (SECRETO): rationale and design. *Eur Stroke J*. 2017;2:116–125. doi: [10.1177/2396987317703210](https://doi.org/10.1177/2396987317703210)